Pharmacological Management of Status Epilepticus

Status epilepticus represents a neurological emergency defined by prolonged or recurrent seizures without recovery of consciousness. Rapid pharmacological intervention is essential to limit neuronal injury, reduce mortality and prevent progression to refractory stages. Initial management centres on benzodiazepines, typically administered intravenously, intramuscularly or via mucosal routes to enhance GABAergic inhibition. When seizures persist, second-line agents such as phenytoin, valproate, levetiracetam or phenobarbital are introduced to stabilise sodium channels or modulate inhibitory and excitatory neurotransmission. The choice of agent depends on efficacy, safety profile, pharmacokinetics and patient factors including age, comorbidities and potential drug interactions. Refractory and super-refractory status epilepticus, in which seizures continue despite first- and second-line treatment, require anaesthetic agents or novel therapies guided by electroencephalographic monitoring. Ongoing research seeks to refine dosing regimens, identify biomarkers of treatment resistance and develop agents that combine rapid onset with minimal adverse effects. Global practice varies, but consensus emphasises early escalation, minimisation of cardiovascular and respiratory compromise, and multidisciplinary protocols to optimise outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Management of Status Epilepticus publication trend

The graph below shows the total number of articles in pharmacological management of status epilepticus across all publications each year (not limited to Nature Index journals).

Technical terms

Status epilepticus: A seizure or series of seizures lasting more than five minutes without recovery of consciousness.

Benzodiazepines: A class of drugs that enhance GABAergic inhibition and serve as first-line treatment in acute seizures.

Refractory status epilepticus: Ongoing seizures after adequate doses of first- and second-line therapies.

Second-line agent: An antiepileptic drug introduced when benzodiazepines fail to terminate seizures.

Electroencephalography (EEG): A monitoring technique that records electrical activity of the brain to guide treatment decisions.

References

1. Phenobarbital in Status epilepticus – Rediscovery of an effective drug. Epilepsy & Behavior (2023).
2. Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence. Journal of Neurology (2022).
3. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial. Journal of Neurology Neurosurgery & Psychiatry (2022).